Study #2021-0774
A Phase 2 Study to evaluate the triplet combination of Pemetrexed plus AB928 (Etrumadenant) + AB122 (zimberelimab) in Patients with Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Pemetrexed, Zimberelimab, Etrumadenant
Description
This is a Phase 2 open-label, single-arm trial for patients with MTAP-deficient advanced urothelial cancer who had received prior immunotherapy. This is a single site study at the University of Texas MD Anderson Cancer Center. This study will allow patients in second line of treatment for advanced urothelial ca or beyond. All patients must have been previously treated with immune checkpoint inhibitor (ICI) therapy as per current standard of care.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Urothelial Carcinoma, Metastatic Cancer
Study phase:
Phase II
Physician name:
Omar Alhalabi
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-844-918-4713
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.